Shining Wang

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

K. Kannan, R. Gregory, M. Levis, 2022, Haematologica.

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

K. Venkatakrishnan, D. Camidge, Pingkuan Zhang, 2022, Clinical and translational science.

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

F. Bosch, L. Gordon, J. Radford, 2020, Clinical Cancer Research.

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)

F. Bosch, L. Gordon, J. Radford, 2023, Oncotarget.

A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C

D. Ryan, A. Parikh, B. Bahamon, 2023, Cancer Chemotherapy and Pharmacology.